2021 research period for North America is officially open
March 24, 2021
Research team is now accepting firm submissions, due June 1
6 West Hubbard Street
Suite 500
Chicago, Illinois 60654
,
Tel: +1(312)527 2157
Fax: +1(312)527 4205
Website: www.rmmslegal.com
RMMS consists of over 30 attorneys focused exclusively in the field of pharmaceutical and biopharmaceutical patent and regulatory counseling, and litigation under Hatch-Waxman, the Medicare Modernization Act (MMA), the Biologics Price Competition and Innovation Act (BPCIA), as well as post-grant review before the Patent Trial and Appeal Board.
RMMS attorneys embrace the science of a case, and make it an integral part of our winning strategy. Indeed, a majority of our attorneys have technical degrees or backgrounds in a variety of areas and disciplines, including chemistry, biochemistry, biology, molecular biology, microbiology, genetics, bacteriology, bioengineering, biomedical engineering, chemical engineering and pharmacy, and many of our attorneys are registered with the USPTO. RMMS also employs full-time Ph.D. technical advisors specializing in chemistry, biological sciences, and pharmaceutics/pharmacy.
Our experience is unparalleled in the industry. Since the firm’s inception over 15 years ago, RMMS has handled over 300 Hatch-Waxman/BPCIA and related pharmaceutical litigation matters (including declaratory judgment, patent infringement, Administrative Procedure Act (APA), and commercial dispute matters) involving at least 160 different drug products for over 25 pharmaceutical clients. In addition to our substantial litigation experience, our attorneys also have extensive regulatory and legislative experience.
We understand that patent litigation is not an end-game, and that the business decisions made throughout the entire product and patent evaluation, regulatory review, litigation, and commercialization process are equally critical to the company’s strategic plans involving any one product or group of products. Our goals are aligned with those of our clients: to ensure that each client obtains value from its applications, whether through the eventual commercial marketing of the product, the sale or assignment of the asset, or relationship-building with other companies through joint development agreements, active pharmaceutical ingredient (API) and finished dosage form supply agreements, licensing agreements, and co-promotion and marketing agreements.
Last Updated September 2019
US
Hatch-Waxman Patent Litigation (Generic)
| Hatch-Waxman Patent Litigation (Generic) — Highly Recommended |
|---|
| Goodwin Procter |
| Knobbe Martens |
| Rakoczy Molino Mazzochi Siwik |
| Sterne Kessler Goldstein & Fox |
| Wilson Sonsini Goodrich & Rosati |
| Winston & Strawn |
| Hatch-Waxman Patent Litigation (Generic) — Recommended |
|---|
| Axinn Veltrop & Harkrider |
| Greenberg Traurig |
| Morrison & Foerster |
| Perkins Coie |
| Robins Kaplan |
| Rothwell Figg Ernst & Manbeck |
| Taft Stettinius & Hollister |
| Willkie Farr & Gallagher |
| Lawyer | Section | Practice Area | Location |
|---|---|---|---|
| Hunt, Eric | Intellectual Property | General Patent Litigation, Hatch-Waxman Patent Litigation | Chicago |
| Mazzochi, Deanne | Intellectual Property | Hatch-Waxman Patent Litigation | Chicago |
| Molino, Paul J | Intellectual Property | Patent Strategy & Management, General Patent Litigation, Hatch-Waxman Patent Litigation | Chicago |
| Rakoczy, William A | Intellectual Property | General Patent Litigation, Hatch-Waxman Patent Litigation | Chicago |
| , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} |
Intellectual Property
"Rakoczy Molino Mazzochi Siwik is the firm we go to for complex and challenging legal issues," a pharmaceutical client says about the patent litigation-focused IP boutique. "They provide comprehensive, well-thought-out and strategic advice on the most complex and challenging legal issues in the pharmaceutical industry." The firm, based in Chicago, receives top-tier ranking as a practice for Hatch-Waxman litigation, and was shortlisted for the Generic Firm of the Year award in 2020. The firm is best known for representing generic pharmaceutical clients, but is also becoming active in the biosimilar litigation arena.
William Rakoczy is recognized as a leading patent litigator in the life sciences industry, underscored by his honor this year as one of a few inductees into the LMG Life Sciences Hall of Fame. The recognition highlights his stellar career as a courtroom advocate for companies in the pharmaceutical area. Mr Rakoczy and LMG Life Sciences newcomer Eric Hunt were recently active for Mylan in a biosimilar litigation, the first matter under the BPCIA for the client.
Paul Molino is managing partner of the firm and another one of the group's experienced litigators. He and Mr Rakoczy are currently active for Apotex, Sandoz and Dr Reddy’s in connection with patent infringement claims brought by Astellas and Gilead. The consolidated matter is currently scheduled for trial in 2021.